Relmada Therapeutics (RLMD) Non-Current Debt (2014 - 2019)
Relmada Therapeutics (RLMD) posted quarterly Non-Current Debt of $110200.0 for Q4 2019, down 3.92% year-over-year from $114700.0 in Q4 2018, and down 56.94% quarter-over-quarter from $255900.0 in Q3 2019.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Non-Current Debt (2014 - 2019) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Non-Current Debt for 6 consecutive years, with $110200.0 the latest figure, recorded in Q4 2019.
- In Q4 2019, Non-Current Debt fell 3.92% year-over-year to $110200.0; the TTM figure through Dec 2019 stood at $110200.0 (down 3.92% YoY), while the FY2019 annual figure was $110200.0, changed N/A from the prior year.
- Non-Current Debt slipped to $110200.0 in Q4 2019 per RLMD's latest filing, from $255900.0 in the prior quarter.
- Across five years, Non-Current Debt topped out at $3.2 million in Q3 2018 and bottomed at $27600.0 in Q1 2017.
- Historically, Non-Current Debt has averaged $428753.1 across 5 years, with a median of $216150.0 in 2015.
- Annual changes were most pronounced in 2017 — Non-Current Debt soared 1061.55% — and 2019, when it plunged 91.99%.
- Relmada Therapeutics' Non-Current Debt stood at $88500.0 in 2015, then increased by 24.29% to $110000.0 in 2016, then jumped by 1061.55% to $1.3 million in 2017, then tumbled by 91.02% to $114700.0 in 2018, then slipped by 3.92% to $110200.0 in 2019.
- Business Quant data shows RLMD's Non-Current Debt at $110200.0 in Q4 2019, $255900.0 in Q3 2019, and $364200.0 in Q2 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 882.16 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 8.96 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | 110,200.00 |
| Sep 30, 2019 | 255,900.00 |
| Jun 30, 2019 | 364,200.00 |
| Mar 31, 2019 | 28,800.00 |
| Dec 31, 2018 | 114,700.00 |
| Sep 30, 2018 | 3.19 Mn |
| Jun 30, 2018 | 2.66 Mn |
| Mar 31, 2018 | 1.58 Mn |
| Dec 31, 2017 | 1.28 Mn |
| Sep 30, 2017 | 678,875.00 |
| Jun 30, 2017 | 276,700.00 |
| Mar 31, 2017 | 27,600.00 |
| Dec 31, 2016 | 110,000.00 |
| Sep 30, 2016 | 164,400.00 |
| Jun 30, 2016 | 273,700.00 |
| Dec 31, 2015 | 88,500.00 |
| Sep 30, 2015 | 176,400.00 |
| Jun 30, 2015 | 263,800.00 |
| Jun 30, 2014 | 58,400.00 |